Source: MarketScreener

Salix Pharmaceuticals: New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy

( Research Reveals Reduction in Hospitalization Rates, Length of Stay and Health Care Costs When Treating OIC with FDA-Approved Prescription Medications LAVAL, QC, March 24, 2022 /PRNewswire/ -- Bausch Health Companies Inc. "Bausch Health" and its gastroenterology business, Salix Pharmaceuticals , one of the largest specialty pharmaceutical...

Read full article »
Est. Annual Revenue
Est. Employees
Robert Spurr's photo - President of Salix Pharmaceuticals


Robert Spurr

CEO Approval Rating


Read more